Ignite Creation Date:
2024-05-06 @ 2:08 AM
Last Modification Date:
2024-10-26 @ 11:14 AM
Study NCT ID:
NCT01979445
Status:
COMPLETED
Last Update Posted:
2020-02-26
First Post:
2013-11-01
Brief Title:
Cangrelor to Clopidogrel or Prasugrel Transition Study
Sponsor:
The Medicines Company
Organization:
The Medicines Company
Study Overview
Official Title:
A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BRIDGE
Brief Summary:
There are two separate objectives in this study
1 To demonstrate the pharmacodynamic PD profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes min after cangrelor infusion is discontinued
2 To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion
1 To demonstrate the pharmacodynamic PD profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes min after cangrelor infusion is discontinued
2 To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None